Castrate Resistant Prostate Market, By Therapy, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

Description

REPORT HIGHLIGHT

The Castrate-Resistant Prostate Market was valued at USD 8,904.54 million in 2023 and expanded at a CAGR of 8.70% from 2024 to 2032.

Castration-resistant prostate cancer (CRPC) represents an advanced stage of prostate cancer. In cases of CRPC, the cancer exhibits limited responsiveness to therapies aimed at reducing testosterone levels. Indicators of progression, such as an increasing prostate-specific antigen (PSA) level, can occur despite diminished testosterone. Generally, CRPC is associated with a less favorable prognosis than hormone-sensitive prostate cancer, as it tends to be more aggressive and prone to metastasis. Current research efforts are directed toward elucidating the mechanisms underlying resistance to androgen deprivation and creating innovative treatment options that target these pathways.

Castrate Resistant Prostate Market- Market Dynamics

Increasing early detection of prostate cancer is expected to propel market growth.

Early detection facilitates prompt intervention through androgen deprivation therapies (ADT) or alternative treatments during the initial stages of prostate cancer. Nevertheless, certain cases will progress to castration-resistant prostate cancer (CRPC) despite initial therapies, yet early intervention may contribute to prolonged patient survival. While prostate cancer can pose significant health risks, the majority of men diagnosed with the disease do not succumb to it. According to the American Cancer Society, projections for prostate cancer in the United States for 2024 indicate approximately 299,010 new cases and around 35,250 fatalities attributed to the disease. Additionally, the emergence of novel therapies and advancements in diagnostic technologies may open new pathways for market expansion. However, limited awareness and diagnostic capabilities in developing regions could hinder market growth.

Castrate Resistant Prostate Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.70% over the forecast period (2024-2032)

Based on Therapy segmentation, Hormonal Therapy was the leading Drug Class in 2023

Based on region, North America was the leading revenue generator in 2023

Castrate Resistant Prostate Market- Segmentation Analysis:

The Global Castrate Resistant Prostate Market is segmented based on Therapy, Distribution channel, and Region.

The market is segmented into four distinct categories according to therapy type: Chemotherapy, Hormonal Therapy, Immunotherapy, and Radiotherapy. Hormonal Therapy holds a predominant position in the market. This form of therapy is essential in the management of Castrate-Resistant Prostate Cancer (CRPC), given that the progression of prostate cancer is primarily influenced by androgen hormones, particularly testosterone.

The market is segmented into four categories according to the Distribution Channel: Hospitals, Cancer Treatment Centers, Retail Pharmacies, and Online Pharmacies. Hospitals and cancer treatment centers continue to play a vital role in delivering advanced and specialized care, whereas retail and online pharmacies are increasingly significant as a growing number of patients opt for outpatient treatment management.

Castrate Resistant Prostate Market- Geographical Insights

This market is geographically extensive, encompassing North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These areas are further categorized based on the countries contributing to business activities. North America leads in market expansion, primarily due to rising healthcare expenditures and enhanced access to treatment options. The significant increase in healthcare spending in North America, especially in the United States and Canada, is crucial to the growth of the CRPC market. Elevated healthcare budgets facilitate greater investment in state-of-the-art medical treatments, advanced diagnostic tools, and innovative therapies for CRPC. According to National Health Expenditures, healthcare spending in the U.S. rose by 4.1% to USD 4.5 trillion in 2022, outpacing the 3.2% increase observed in 2021, although it remains considerably lower than the 10.6% surge in 2020. Europe ranks as the second-largest region for market growth, driven by a growing preference for outpatient care.

Castrate Resistant Prostate Market- Competitive Landscape:

The market for castrate-resistant prostate cancer (CRPC) is marked by significant competition among pharmaceutical and biopharmaceutical companies dedicated to the development and commercialization of innovative therapies. As numerous established treatments are already present, the market is experiencing a growing saturation, prompting companies to engage in vigorous marketing and promotional strategies to secure a larger share. The emphasis on combination therapies, genetic profiling, and immuno-oncology is expected to further influence the evolving competitive environment.

Recent Developments:

On September 30, 2019, findings released in the New England Journal of Medicine indicated that patients suffering from metastatic castration-resistant prostate cancer (mCRPC) who had previously undergone treatment with docetaxel and exhibited disease progression within 12 months while on an androgen receptor (AR)-targeted therapy (either abiraterone or enzalutamide) demonstrated a notably extended radiographic progression-free survival (rPFS) when treated with Jevtana (cabazitaxel) in combination with prednisone, in comparison to those receiving abiraterone plus prednisone or enzalutamide.

On January 24, 2024, Johnson & Johnson revealed that new clinical and real-world evidence will be presented in 18 abstracts at the upcoming ASCO GU Symposium, scheduled to take place in San Francisco from January 25 to 27. This announcement underscores the Company's dedication to advancing the research in genitourinary (GU) cancers.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CASTRATE-RESISTANT PROSTATE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Sanofi
Johnson & Johnson Services, Inc.
Pfizer, Inc.
Astellas Pharma, Inc.
Bayer AG
Phinergy
Others

GLOBAL CASTRATE RESISTANT PROSTATE MARKET, BY THERAPY- MARKET ANALYSIS, 2019 - 2032

Chemotherapy
Hormonal Therapy
Immunotherapy
Radiotherapy

GLOBAL CASTRATE RESISTANT PROSTATE MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Hospitals
Cancer Treatment Centers
Retail Pharmacies
Online Pharmacies

GLOBAL CASTRATE RESISTANT PROSTATE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV4182

1. Castrate Resistant Prostate Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Castrate Resistant Prostate Market Snippet by Therapy
- 2.1.2. Castrate Resistant Prostate Market Snippet by Distribution Channel
- 2.1.3. Castrate Resistant Prostate Market Snippet by Country
- 2.1.4. Castrate Resistant Prostate Market Snippet by Region
2.2. Competitive Insights

3. Castrate Resistant Prostate Key Market Trends

3.1. Castrate Resistant Prostate Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Castrate Resistant Prostate Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Castrate Resistant Prostate Market Opportunities
3.4. Castrate Resistant Prostate Market Future Trends

4. Castrate Resistant Prostate Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Castrate Resistant Prostate Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Castrate Resistant Prostate Market Landscape

6.1. Castrate Resistant Prostate Market Share Analysis, 2022
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Castrate Resistant Prostate Market - By Therapy

7.1. Overview
- 7.1.1. Segment Share Analysis, By Therapy, 2022 & 2030 (%)
- 7.1.2. Chemotherapy
- 7.1.3. Hormonal Therapy
- 7.1.4. Immunotherapy
- 7.1.5. Radiotherapy

8. Castrate Resistant Prostate Market - By Distribution Channel

8.1. Overview
- 8.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
- 8.1.2. Hospitals
- 8.1.3. Cancer Treatment Centers
- 8.1.4. Retail Pharmacies
- 8.1.5. Online Pharmacies

9. Castrate Resistant Prostate Market- By Geography

9.1. Introduction
- 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
9.2. North America
- 9.2.1. Overview
- 9.2.2. Castrate Resistant Prostate Key Manufacturers in North America
- 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 9.2.4. North America Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
- 9.2.5. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.2.6. U.S.
  - 9.2.6.1. Overview
  - 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.2.6.3. U.S. Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.2.6.4. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.2.7. Canada
  - 9.2.7.1. Overview
  - 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.2.7.3. Canada Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.2.7.4. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
9.3. Europe
- 9.3.1. Overview
- 9.3.2. Castrate Resistant Prostate Key Manufacturers in Europe
- 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 9.3.4. Europe Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
- 9.3.5. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.3.6. Germany
  - 9.3.6.1. Overview
  - 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.3.6.3. Germany Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.3.6.4. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.3.7. Italy
  - 9.3.7.1. Overview
  - 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.3.7.3. Italy Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.3.7.4. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.3.8. United Kingdom
  - 9.3.8.1. Overview
  - 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.3.8.3. United Kingdom Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.3.8.4. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.3.9. France
  - 9.3.9.1. Overview
  - 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.3.9.3. France Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.3.9.4. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.3.10. Russia
  - 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.3.10.2. Russia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.3.10.3. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.3.11. Netherlands
  - 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.3.11.2. Netherlands Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.3.11.3. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.3.12. Sweden
  - 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.3.12.2. Sweden Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.3.12.3. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.3.13. Poland
  - 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.3.13.2. Poland Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.3.13.3. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.3.14. Rest of Europe
  - 9.3.14.1. Overview
  - 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.3.14.3. Rest of the Europe Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.3.14.4. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
9.4. Asia Pacific (APAC)
- 9.4.1. Overview
- 9.4.2. Castrate Resistant Prostate Key Manufacturers in Asia Pacific
- 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 9.4.4. Asia Pacific Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
- 9.4.5. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.4.6. India
  - 9.4.6.1. Overview
  - 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.4.6.3. India Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.4.6.4. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.4.7. China
  - 9.4.7.1. Overview
  - 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.4.7.3. China Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.4.7.4. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.4.8. Japan
  - 9.4.8.1. Overview
  - 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.4.8.3. Japan Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.4.8.4. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.4.9. South Korea
  - 9.4.9.1. Overview
  - 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.4.9.3. South Korea Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.4.9.4. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.4.10. Australia
  - 9.4.10.1. Overview
  - 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.4.10.3. Australia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.4.10.4. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.4.11. Thailand
  - 9.4.11.1. Overview
  - 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.4.11.3. Thailand Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.4.11.4. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.4.12. Indonesia
  - 9.4.12.1. Overview
  - 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.4.12.3. Indonesia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.4.12.4. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.4.13. Philippines
  - 9.4.13.1. Overview
  - 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.4.13.3. Philippines Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.4.13.4. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.4.14. Rest of APAC
  - 9.4.14.1. Overview
  - 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.4.14.3. Rest of APAC Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.4.14.4. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
9.5. Latin America
- 9.5.1. Overview
- 9.5.2. Castrate Resistant Prostate Key Manufacturers in Latin America
- 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 9.5.4. Latin America Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
- 9.5.5. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.5.6. Brazil
  - 9.5.6.1. Overview
  - 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.5.6.3. Brazil Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.5.6.4. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.5.7. Mexico
  - 9.5.7.1. Overview
  - 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.5.7.3. Mexico Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.5.7.4. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.5.8. Argentina
  - 9.5.8.1. Overview
  - 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.5.8.3. Argentina Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.5.8.4. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.5.9. Colombia
  - 9.5.9.1. Overview
  - 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.5.9.3. Colombia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.5.9.4. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.5.10. Rest of LATAM
  - 9.5.10.1. Overview
  - 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.5.10.3. Rest of LATAM Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.5.10.4. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
9.6. Middle East and Africa
- 9.6.1. Overview
- 9.6.2. Castrate Resistant Prostate Key Manufacturers in Middle East and Africa
- 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 9.6.4. Middle East and Africa Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
- 9.6.5. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.6.6. Saudi Arabia
  - 9.6.6.1. Overview
  - 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.6.6.3. Saudi Arabia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.6.6.4. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.6.7. United Arab Emirates
  - 9.6.7.1. Overview
  - 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.6.7.3. United Arab Emirates Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.6.7.4. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.6.8. Israel
  - 9.6.8.1. Overview
  - 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.6.8.3. Israel Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.6.8.4. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.6.9. Turkey
  - 9.6.9.1. Overview
  - 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.6.9.3. Turkey Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.6.9.4. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.6.10. Algeria
  - 9.6.10.1. Overview
  - 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.6.10.3. Algeria Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.6.10.4. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.6.11. Egypt
  - 9.6.11.1. Overview
  - 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.6.11.3. Egypt Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.6.11.4. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 9.6.12. Rest of MEA
  - 9.6.12.1. Overview
  - 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
  - 9.6.12.3. Rest of MEA Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
  - 9.6.12.4. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

10. Key Vendor Analysis- Castrate Resistant Prostate Industry

10.1. Competitive Dashboard
10.2. Company Profiles
- 10.2.1. Sanofi
- 10.2.2. Johnson & Johnson Services, Inc.
- 10.2.3. Pfizer, Inc.
- 10.2.4. Astellas Pharma, Inc.
- 10.2.5. Bayer AG
- 10.2.6. Phinergy
- 10.2.7. Others

11. 360 Degree Analyst View

12. Appendix

12.1. Research Methodology
12.2. References
12.3. Abbreviations
12.4. Disclaimer
12.5. Contact Us